National Pharmaceutical Council (NPC) Chief Science Officer Robert W. Dubois, M.D., Ph.D., today debuted a column, "From Methods to Policy," in the new peer-reviewed, bimonthly publication, Journal of Comparative Effectiveness Research. Dr. Dubois also serves as an associate editor for the Journal.In his first column, Dr. Dubois outlines "the intended and unintended consequences of CER," as a way to spur further dialogue about the shape CER takes and how it ultimately impacts health care. In coming issues, Dr. Dubois' column will take a closer look at some of the challenges related to conducting, translating and disseminating CER."CER has great potential to improve medical decision-making and as a result our overall health. However, the detail of how we implement and use CER is critical to achieving this goal," wrote Dr. Dubois. "The idea of this column is to maintain a proper focus on the progress of CER as a tool for better health care, and where appropriate, shed light on the times when the CER debate goes in the wrong direction."The Journal is published by Future Medicine Ltd., based in North London, UK. Selected content from the launch issue can be viewed at http://www.futuremedicine.com/toc/cer/1/1 . To receive a free 30-day online trial to evaluate the Journal's content, please contact info@futuremedicine.com, with PRESSCER in the subject line.
Subscribe to:
Post Comments (Atom)
Superhit News
-
US health regulator USFDA has issued a warning letter to German drug firm Fresenius Kabi AG for lapses at its drug manufacturing fac...
-
Goods and Service Tax (GST) is high on the agenda for the new government and its rollout is a priority. GST will benefit the Indian pharma...
-
Rib-X Pharmaceuticals, Inc. announced today the signature of an exclusive worldwide research collaboration agreement and option for license ...
-
Physiomics: Reports difficult trading but highlights growing interest from big pharmaceutical groupsPhysiomics ( LON:PYC ) said that trading conditions were difficult in the six months ended 31 December 2010, but it believes it is in a be...
-
Hindusthan National Glass and Industries Ltd is expected to finalize a strategic overseas acquisition in the pharmaceuticals space in the n...
-
The Minister of State (Health and Family Welfare), Sh Ashwini Kumar Choubey through a written reply in the Lok Sabha informed about th...
-
India's Central Drugs Standard Control Organization (CDSCO) has suspended the manufacturing of eye drops at the Chennai-based firm after...
-
The government is hoping to see the implementation of the track and trace system for domestic and export supply chain in another one y...
-
Diclofenac injection is a painkiller which is manufactured by Themis Medicare Ltd and marketed by Novartis India under the brand name ...
-
Amylin Pharmaceuticals, Inc. AMLN +16.15% and Alkermes plc ALKS +4.61% today announced that the U.S. Food and Drug Administration (FDA) has ...
No comments:
Post a Comment